Stay updated with breaking news from Laura mittmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(0) Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further build the company s clinical expertise. Dr. Fingerle-Rowson is an experienced hematologist and medical oncologist who brings to Tubulis more than two decades of academic, biotechnology and pharmaceutical industry experience. Moreover, he has a proven track record of advancing product candidates from early clinical phase through regulatory approval and into clinical practice. In this newly established role, he will use his extensive knowledge in the development of cancer therapeutics to oversee Tubulis clinical activities and advance the company s Antibody Drug Conjugates (ADCs) towards clinical evaluation. ....
Ethris Announces Positive Scientific Review of its mRNA-Based COVID-19 Therapeutic Program Application to Bavarian BayTherapie2020 Grant Program apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March 14 March 17, 2021. The data was previously presented at the American Society of Hematology in December 2020. MaaT013 is an enema formulation of a full ecosystem microbiota biotherapeutic characterized by a consistent high diversity and richness of microbial species derived from pooled healthy donors The results include data from 29 patients with gastrointestinal, acute Graft-versu ....
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan AgomAb Therapeutics N.V. announced today the closing of a $74 million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth of the company s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with ....
(1) Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort Study is evaluating safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy MaaT Pharma announced today that an independent Data Safety and Monitoring Board (DSMB) completed its first analysis of the ongoing Phase Ib CIMON clinical trial with MaaT033, the company s capsule formulation of its lead biotherapeutic, MaaT013, in patients with acute myeloid leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS) following intensive chemotherapy. The DSMB reviewed safety data from the first patient cohort treated with the first dose of MaaT033 and confirmed the absence of safety issues during the trial and recommended that the trial continue without modifications. ....